Citation Impact
Citing Papers
Prospective identification of tumorigenic breast cancer cells
2003 Standout
Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast Cancer
2008
Quantitative prediction of drug toxicity in humans from toxicology in small and large animals.
1975
Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data
1997 Standout
Facts and Controversies in Systemic Treatment of Metastatic Breast Cancer
2004
Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.
1991
The transcriptional repressor Snail promotes mammary tumor recurrence
2005
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
2007 Standout
Gene expression profiling predicts clinical outcome of breast cancer
2002 StandoutNature
Natural History of Small Untreated Hepatocellular Carcinoma in Cirrhosis: A Multivariate Analysis of Prognostic Factors of Tumor Growth Rate and Patient Survival
1992
Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis
2002 Standout
Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer
2000
HER2 and Responsiveness of Breast Cancer to Adjuvant Chemotherapy
2006
A view on drug resistance in cancer
2019 StandoutNature
Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma
2002 Standout
Stem cells, cancer, and cancer stem cells
2001 StandoutNature
Chemoradiotherapy after Surgery Compared with Surgery Alone for Adenocarcinoma of the Stomach or Gastroesophageal Junction
2001 Standout
Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study.
1998
Epithelial-Mesenchymal Transitions in Development and Disease
2009 Standout
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
2011 StandoutNature
Clinical evaluation of 5-HT3 receptor antagonists as anti-emetics
1991
A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial
2005
The effect of gamma-linolenic acid, an in vitro cytostatic substance contained in evening primrose oil, on primary liver cancer. A double-blind placebo controlled trial
1990
Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative.
1996 Standout
Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer
1996 Standout
Cancer Metastasis: Building a Framework
2006 Standout
Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women.
1998
Development of Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying Immunoreceptor
1999 StandoutNobel
Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival
2003 Standout
Metabolism and action of amino acid analog anti-cancer agents
1990
The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03.
1993
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
The usefulness of CA15.3, mucin-like carcinoma-associated antigen and carcinoembryonic antigen in determining the clinical course in patients with metastatic breast cancer
1995
Serum tissue polypeptide specific antigen (TPS): a complementary tumor marker to CA 15-3 in the management of breast cancer
2001
HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma.
1992
Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer
2010 Standout
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
2004 Standout
Hepatocellular carcinoma
1992
CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma
2002 Standout
A Prospective Randomized Administration of 5′-Deoxy-5-fluorouridine as Adjuvant Chemotherapy for Hepatocellular Carcinoma Treated with Transcatheter Arterial Chemoembolization
1997
A randomised study of carboplatin vs sequential ifosfamide/carboplatin for patients with FIGO stage III epithelial ovarian carcinoma
1993
Primary treatment of hepatocellular carcinoma by arterial chemoembolization
1992
A phase II study
2000
Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens
1993
Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study.
1997
Epidermal Growth Factor (EGF) Receptor-dependent ERK Activation by G Protein-coupled Receptors
2001 StandoutNobel
Loss of Retinoic Acid Receptor-β Expression Is an Early Event during Esophageal Carcinogenesis
1999
Adjuvant chemotherapy for soft-tissue sarcoma: review and meta-analysis of the published results of randomised clinical trials
1995
Increased plasma viscosity as a reason for inappropriate erythropoietin formation.
1993 StandoutNobel
Ectopic Expression of Nonliganded Retinoic Acid Receptor β Abrogates AP-1 Activity by Selective Degradation of c-Jun in Cervical Carcinoma Cells
2004 StandoutNobel
Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma—A randomized controlled trial
1988
Treatment of hepatocellular carcinoma: A systematic review of randomized controlled trials
1997
Historical perspective on hormonal therapy of advanced breast cancer
2002
Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function
1995
Tamoxifen and Chemotherapy for Lymph Node-Negative, Estrogen Receptor-Positive Breast Cancer
1997
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
2004 Standout
Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with Cirrhosis
1996 Standout
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial
2001
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
2010 Standout
Survival analysis in natural history studies of disease
1989
Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16.
1990
EMT: 2016
2016 Standout
Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy
2003
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
2004 Standout
Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases.
1991
Angiogenesis and Blood Vessel Invasion as Prognostic Indicators for Node-Negative Breast Cancer
2001
Chronic Eosinophilic Leukemias and the Myeloproliferative Variant of the Hypereosinophilic Syndrome
2007
Prevalence and outcomes of anemia in cancer: a systematic review of the literature
2004
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
2010 Standout
Assessment of CA 15.3, CEA and TPA Concentrations during Monitoring of Breast Cancer
2000
Mortality In Sickle Cell Disease -- Life Expectancy and Risk Factors for Early Death
1994 Standout
Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation
1994
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
2010 Standout
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
2001 Standout
Natural History of Untreated Nonsurgical Hepatocellular Carcinoma: Rationale for the Design and Evaluation of Therapeutic Trials
1999
Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma
1992
Randomized comparison of doxorubicin and vindesine to doxorubicin for patients with metastatic soft-tissue sarcomas
1990
Quantifying heterogeneity in a meta‐analysis
2002 Standout
DNA Flow Cytometry Does Not Predict 5- or 10-Year Recurrence Rates for T1-2 Node-Negative Breast Cancer
2000
Myeloproliferative Disorders with Translocations of Chromosome 5q31–35: Role of the Platelet-Derived Growth Factor Receptor Beta
2002
Improving the Quality of Life during Chemotherapy for Advanced Breast Cancer
1987
Mitoxantrone
1996
Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases
2006
Tumor Markers in Breast Cancer – European Group on Tumor Markers Recommendations
2005
Treatment of hepatocellular carcinoma using doxorubicin/ethiodized oil/gelatin powder chemoembolization
1993
Prognostic factors in metastatic melanoma
1993
Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma.
1994
clinical experience with procarbazine in Hodgkin's disease, reticulum cell sarcoma, and lymphosarcoma
1970
Diagnosis and Management of the Metabolic Syndrome
2005 Standout
Hepatocellular Carcinoma
2019 Standout
Cancer of the Breast
1980
Chemotherapy studies in primary liver cancer. A prospective randomized clinical trial
1978
A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study.
1985
Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials
2008
Breast Cancer Prognosis Determined by Gene Expression Profiling: A Quantitative Reverse Transcriptase Polymerase Chain Reaction Study
2005
Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer
1998
A comparison of combination chemotherapy and combined modality therapy for locally advanced gastric carcinoma
1982
Phase III Trial of Gemcitabine Plus Cisplatin Versus Cisplatin Alone in Patients With Locally Advanced or Metastatic Non–Small-Cell Lung Cancer
2000
Platelets and cancer
2002
Primary Structure And Functional Expression of the 5HT 3 Receptor, A Serotonin-gated Ion Channel
1991 StandoutScienceNobel
Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival
2006
Ethnic differences in the behavior of hepatocellular carcinoma
1999
The Current Status and Future Prospects of Treatment for Multiple Myeloma
1982
Synergistic interaction between cisplatin and gemcitabine in vitro.
1996
Prevention of Apoptosis by Bcl-2: Release of Cytochrome c from Mitochondria Blocked
1997 StandoutScience
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
2009 Standout
Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer.
1986
Simultaneous Immunohistochemical Detection of Tumor Cells in Lymph Nodes and Bone Marrow Aspirates in Breast Cancer and Its Correlation With Other Prognostic Factors
2001
Comparison of induction chemotherapies for metastatic breast cancer. An eastern cooperative oncology group trial
1982
Effect of calcium antagonists on the chemosensitivity of two multidrug-resistant human tumour cell lines which do not overexpress P-glycoprotein
1989
Adriamycin versus methotrexate in five-drug combination chemotherapy for advanced breast cancer. A randomized trial
1978
Expression and Prognostic Significance of Metalloproteinases and Their Tissue Inhibitors in Patients With Small-Cell Lung Cancer
1999
Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: A randomized, controlled trial
1995
The importance of dose intensity in chemotherapy of metastatic breast cancer.
1984 Standout
Phase II trial of high-dose chemotherapy with autologous stem cell transplant for stage IV breast cancer with minimal metastatic disease.
1999
National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000
2001
Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial.
1987
High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993
1999 Standout
Adriamycin combinations in advanced breast cancer:A southwest oncology group study
1982
Combined chemo- and hormonal therapy in advanced breast cancer
1977
Proposal for classifying the acute emetogenicity of cancer chemotherapy.
1997 Standout
Adjuvant Chemotherapy for Soft Tissue Sarcomas
1991
The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.
1992 Standout
Vincristine, doxorubicin, and cyclophosphamide versus low-dose intravenous cyclophosphamide, methotrexate, and 5-fluorouracil in advanced breast cancer. A randomized trial of the piedmont oncology association
1982
Cisplatin combination chemotherapy versus chlorambucil in advanced ovarian carcinoma: mature results of a randomized trial.
1985
Adenocarcinoma of the stomach: Areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy
1982
Adjuvant Therapy Of Soft-Tissue Sarcomas
1995
Biological markers in breast carcinoma:III. Clinical correlations with carcinoembryonic antigen
1977
The treatment of soft tissue sarcomas with focus on chemotherapy: A review
1986
A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study.
2001
Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations
2002 StandoutScience
Review article: overview of medical treatments in unresectable hepatocellular carcinoma—an impossible meta‐analysis?
1998
BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1α activation
2018 StandoutNobel
A comparison of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone (CMFVP) in patients with advanced breast cancer
1983
A controlled study in the use of combined drug therapy for metastatic breast cancer
1975
Protein tyrosine phosphatase containing SH2 domains: characterization, preferential expression in hematopoietic cells, and localization to human chromosome 12p12-p13.
1992
Meta-analysis of the role of platinum compounds in advanced ovarian carcinoma. The Advanced Ovarian Cancer Trialists Group.
1992
Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer.
1988
Etoposide (VP-16–213)
1985
Enzymatic aminoacylation of tRNA with unnatural amino acids
2006 StandoutNobel
Tyrosine Kinase Inhibition: An Approach to Drug Development
1995 Science
The Combination of p53 Mutation and neu/erbB-2 Amplification Is Associated With Poor Survival in Node-Negative Breast Cancer
2003
The Anthracycline Antineoplastic Drugs
1981 Standout
Integrating Genetic Approaches into the Discovery of Anticancer Drugs
1997 StandoutScienceNobel
A Transmembrane Intracellular Estrogen Receptor Mediates Rapid Cell Signaling
2005 StandoutScience
What treatment for elderly patients with aggressive lymphoma?
1994
Combination chemotherapy using adriamycin, DTIC, cyclophosphamide, and actinomycin D for advanced soft tissue sarcomas: a randomized comparative trial. A phase III, Southwest Oncology Group Study (7613).
1987
Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line
1992 StandoutScience
Works of Geoffrey Falkson being referenced
Ten-year follow-up study of premenopausal women with metastatic breast cancer: an Eastern Cooperative Oncology Group study.
1995
Abnormalities of chromosome 12p 13 and malignant proliferation of eosinophils: a nonrandom association
1987
A study of fadrozole, a new aromatase inhibitor, in postmenopausal women with advanced metastatic breast cancer.
1992
A Randomized Phase II Study of Acivicin and 4ʼDeoxydoxorubicin in Patients with Hepatocellular Carcinoma in an Eastern Cooperative Oncology Group Study
1990
Small Cell Lung Cancer: Analysis of Factors Influencing the Response to Treatment and Survival
1994
Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: an Eastern Cooperative Oncology Group phase III study.
1990
Long-term survival of patients treated with combination chemotherapy for metastatic breast cancer
1991
A phase I study of a new 5HT3-receptor antagonist, BRL43694A, an agent for the prevention of chemotherapy-induced nausea and vomiting
1989
Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma.
1991
13-Cis-retinoic acid and interferon alpha-2a in patients with advanced esophageal cancer: A phase II trial
1996
Fadrozole hydrochloride, a new nontoxic aromatase inhibitor for the treatment of patients with metastatic breast cancer
1992
Mitoxantrone in the Treatment of Acute Leukemia
1990
Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment.
1998
A Randomized Trial of Mitomycin-C (M) Versus Mitomycin-C Plus High-Dose Medroxyprogesterone Acetate (MMPA) in the Treatment of Patients with Advanced Breast Cancer
1993
Low Serum Testosterone and a Younger Age Predict for a Poor Outcome in Metastatic Prostate Cancer
1997
Recombinant Human Erythropoietin in the Treatment of Cancer-Related Anaemia
1994
Phase II trial of fotemustine in patients with metastatic malignant melanoma
1994
Phase II evaluation of dibromodulcitol and actinomycin D, hydroxyurea, and cyclophosphamide in previously untreated patients with malignant melanoma
1987
Chronological age is a multifactorial prognostic variable in patients with Non-Hodgkin’s Lymphoma
1992
Factors predicting for response, time to treatment failure, and survival in women with metastatic breast cancer treated with DAVTH: a prospective Eastern Cooperative Oncology Group study.
1991
Suramin in combination with mitomycin C in hormone-resistant prostate cancer. A phase II clinical study
1993
Efficacy of Adjuvant Chemotherapy in High-Risk Node-Negative Breast Cancer
1989
Cisplatin, carboplatin, and cyclophosphamide combination chemotherapy in advanced-stage ovarian carcinoma: an Eastern Cooperative Oncology Group pilot study.
1991
Clinical experience with 5-(3,3-bis(2-chloroethyl)-1-triazeno)imidazole-4-carboxamide (NSC-82196) in the treatment of metastatic malignant melanoma.
1972
Extended survival and remission rates in metastatic breast cancer
1971
Dibromodulcitol and Adriamycin ± tamoxifen in advanced breast cancer*
1982
Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study.
1994
Controlled prospective trial of combination chemotherapy with cyclophosphamide, adriamycin, and 5-fluorouracil for the treatment of advanced ovarian cancer: a preliminary report.
1979
PALA in advanced breast cancer A phase II pilot study by the ECOG
1982
Neocarzinostatin versus m-AMSA or doxorubicin in hepatocellular carcinoma.
1984
A randomized comparison of cyclophosphamide, adriamycin, and 5-fluorouracil with triethylenethiophosphoramide and methotrexate, both as sequential and as fixed rotational treatment in patients with advanced ovarian cancer
1985
Phase II trial of acivicin in malignant mesothelioma.
1987
Randomized trial of chlorozotocin, neocarzinostatin, or methyl-CCNU in patients with malignant melanoma
1984
A prospective evaluation of chemohormonal therapy remission maintenance in advanced breast cancer
1981
Age as a prognostic factor in recurrent breast cancer.
1986
Primary liver cancer. An eastern cooperative oncology group trial
1984
Phase II clinical trial of acivicin in advanced breast cancer: an Eastern Cooperative Oncology Group Study.
1986
Improved remission rates and remission duration in young women with metastatic breast cancer following combined oophorectomy and chemotherapy. A study by cancer and leukemia group B
1979
Clinical trial of VP 16–213 (NSC 141540) I.V. Twice weekly in advanced neoplastic disease a study by the cancer and leukemia group B
1980
Fluorouracil, imidazole carboxamide dimethyl triazeno, vincristine, and bis-chloroethyl nitrosourea in colon cancer
1974
Natural History of More Than 20 Years of Node-Positive Primary Breast Carcinoma Treated With Cyclophosphamide, Methotrexate, and Fluorouracil–Based Adjuvant Chemotherapy: A Study by the Cancer and Leukemia Group B
2003
Actual versus ideal weight in the calculation of surface area: effects on dose of 11 chemotherapy agents.
1987
Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.
1998
Some aspects of the use of cytostatic drugs in dermatology.
1966
Prognostic factors for survival in hepatocellular carcinoma.
1988
Intra-arterial chemotherapy in the treatment of primary liver cancer.
1974
Mesnum as a protector against kidney and bladder toxicity with high-dose ifosfamide treatment
1982
A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy
1978
Hepatocellular Carcinoma
1995
Malignant hepatoma in the Bantu
1970
Unexpected toxicity in patients treated with iphosphamide.
1972
FLUOROURACIL AND RADIOTHERAPY IN GASTROINTESTINAL CANCER
1969
Locoregional Failure 10 Years After Mastectomy and Adjuvant Chemotherapy With or Without Tamoxifen Without Irradiation: Experience of the Eastern Cooperative Oncology Group
1999
A comparison of adriamycin versus vincristine and adriamycin, and cyclophosphamide versus vincristine, actinomycin-D, and cyclophosphamide for advanced sarcoma
1982
Adjuvant CMFP versus CMFP plus tamoxifen versus observation alone in postmenopausal, node-positive breast cancer patients: three-year results of an Eastern Cooperative Oncology Group study.
1985
Prospective evaluation of carcinoembryonic antigen levels and alternating chemotherapeutic regimens in metastatic breast cancer.
1986
Prospective evaluation of rotating chemotherapy in advanced breast cancer. An Eastern Cooperative Oncology Group Trial.
1983
Daunorubicin (NSC-83142) versus daunorubicin plus prednisone (NSC-10023) versus daunorubicin plus vincristine (NSC-67574) plus prednisone in advanced childhood acute lymphocytic leukemia.
1972
Carcinoembryonic antigen in patients with breast cancer.An adjunctive tool to monitor response and therapy
1978
Prognostic factors affecting the survival of patients with multiple myeloma. A retrospective analysis of 86 patients.
1991
VM-26, a new anticancer drug with effectiveness in malignant lymphoma: an Eastern Cooperative Oncology Group Study (EST 1474).
1979
FIVB--a new combination of drugs in the treatment of cancer.
1973
Comparison of treatment of metastatic gastrointestinal cancer with 5-fluorouracil (5-FU) to a combination of 5-FU with cytosine arabinoside
1972
Fluorouracil, methyl-ccnu and vincristine in cancer of the colon
1976
Eastern cooperative oncology group experience with chemotherapy for inoperable gallbladder and bile duct cancer
1984
Phase II evaluation of dibromodulcitol, ICRF-159, and maytansine for sarcomas
1982